Galectin Therapeutics (GALT) Total Current Liabilities (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Total Current Liabilities of $7.3 million for Q1 2026, down 93.41% year-over-year from $110.8 million in Q1 2025, and down 9.0% quarter-over-quarter from $8.0 million in Q4 2025.
Galectin Therapeutics (GALT) Total Current Liabilities (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $7.3 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 93.41% year-over-year to $7.3 million; the TTM figure through Mar 2026 stood at $7.3 million (down 93.41% YoY), while the FY2025 annual figure was $8.0 million, down 77.32% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $7.3 million, down from $8.0 million in the prior quarter.
- The five-year high for Total Current Liabilities was $136.4 million in Q3 2025, with the low at $7.3 million in Q1 2026.
- The 5-year median for Total Current Liabilities is $11.5 million (2023), against an average of $26.6 million.
- The sharpest annual moves came in 2025 and 2026: Total Current Liabilities surged 777.38% in 2025, then slumped 93.41% in 2026.
- Galectin Therapeutics' Total Current Liabilities stood at $13.0 million in 2022, then rose by 20.47% to $15.7 million in 2023, then jumped by 125.88% to $35.4 million in 2024, then plunged by 77.32% to $8.0 million in 2025, then dropped by 9.0% to $7.3 million in 2026.
- Business Quant data shows GALT's Total Current Liabilities at $7.3 million in Q1 2026, $8.0 million in Q4 2025, and $136.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | 7.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.31 Mn |
| Dec 31, 2025 | 8.03 Mn |
| Sep 30, 2025 | 136.45 Mn |
| Jun 30, 2025 | 10.77 Mn |
| Mar 31, 2025 | 110.84 Mn |
| Dec 31, 2024 | 35.41 Mn |
| Sep 30, 2024 | 25.26 Mn |
| Jun 30, 2024 | 14.62 Mn |
| Mar 31, 2024 | 12.63 Mn |
| Dec 31, 2023 | 15.68 Mn |
| Sep 30, 2023 | 10.52 Mn |
| Jun 30, 2023 | 9.95 Mn |
| Mar 31, 2023 | 11.53 Mn |
| Dec 31, 2022 | 13.01 Mn |
| Sep 30, 2022 | 9.59 Mn |
| Jun 30, 2022 | 10.89 Mn |
| Mar 31, 2022 | 9.54 Mn |
| Dec 31, 2021 | 9.03 Mn |
| Sep 30, 2021 | 8.30 Mn |
| Jun 30, 2021 | 6.05 Mn |